ImmunoGen announces clinical collaboration with Gilead Sciences

ImmunoGen (IMGN) announced a clinical collaboration with Gilead Sciences (GILD) to evaluate the safety and anti-leukemia activity of pivekimab sunirine in combination with magrolimab, a potential, first-in-class, investigational CD47 inhibitor, in patients with relapsed or refractory CD123-positive acute myeloid leukemia. Expected to initiate in 2023, the collaboration will be a new cohort in ImmunoGen’s 802 study and will evaluate pivekimab in combination with magrolimab in up to 42 patients with R/R CD123-positive AML. The primary endpoint for this cohort is complete response rate. ImmunoGen’s 802 study is an open-label, multicenter, Phase 1b/2 trial to determine the safety and tolerability of pivekimab and assess the anti-leukemia activity of the agent when administered in combination with Vidaza and/or Venclexta in patients with relapsed and frontline CD123-positive AML.